2022年ERS/ATS支气管扩展剂反应指南在喘控制中的影响
Clara Seghers Carreras1, Miguel Jiménez Gómez1, Begoña Peña Del Cura1
1Pulmonology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.
概括
新的支气管扩展剂反应 (BDR) 标准表明严重喘患者的喘控制较差,喘恶化风险更高. 这些更新的指南有助于更好的风险分层和治疗决策,以改善喘管理.
科学领域:
- 肺部病理学 肺部病理学
- 呼吸系统医学 呼吸系统医学
- 临床试验 临床试验
背景情况:
- 控制喘的评估依赖于支气管扩展剂反应 (BDR).
- 以前的BDR标准 (2005年) 可能不准确地反映了当前对喘病理生理学的理解.
- 较新的指导方针 (ERS/ATS 2022) 提出了更新的BDR截止值.
研究的目的:
- 评估新的ERS/ATS 2022 BDR截止值是否与与2005年定义相比更差的喘控制相关.
- 使用这两种标准评估BDR状态和喘恶化风险之间的关联.
主要方法:
- 一项前性研究,涉及198名中度至重度喘患者.
- 用2005年和2022年ERS/ATS值对BDR进行分类的患者.
- 收集的临床数据,肺功能和一年恶化率.
主要成果:
- 根据2022年的标准,与2005年的标准 (23.2%) 相比,BDR患者的数量较少 (19.2%).
- 根据2022标准分类的患者显示喘控制得分明显较低 (p=0.001).
- 2022年标准与2005年标准 (1.09) 相比,与更高的相对恶化风险 (1.23) 相关.
结论:
- 更新的2022年BDR标准似乎是一个更敏感的标记,用于识别患有喘控制较差的患者.
- 这些新标准可能会加强风险分层,并为喘管理中的治疗决策提供信息.
- 利用2022年BDR截止值可能会导致更个性化,更有效的喘疗法.
相关概念视频
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
1.6K
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
1.6K
01:30Asthma-IV: Diagnostic and Management
3.1K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.1K
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
1.7K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.7K
01:26COPD: Management Using Bronchodilators and Corticosteroids
741
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
741
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
1.5K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
1.5K
01:17Drugs Used in Lower Respiratory Disorders: Overview
1.1K
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
1.1K